Verastem Oncology's AVMAPKI-FAKZYNJA Combo Shows Durable Efficacy in LGSOC
Event summary
- Two-year median follow-up data from the RAMP 201 study published in Gynecologic Oncology, showing durable responses in recurrent low-grade serous ovarian cancer (LGSOC).
- Median duration of response (mDoR) for KRAS wild-type LGSOC increased from 9.2 to 12 months, with 50% of KRAS-mutated and 30% of KRAS wild-type patients remaining on therapy for over a year.
- No new safety signals observed, with a 12% discontinuation rate due to adverse events.
- AVMAPKI-FAKZYNJA CO-PACK received FDA accelerated approval in May 2025 for KRAS-mutated recurrent LGSOC.
The big picture
Verastem Oncology's long-term data reinforces the clinical benefit of its AVMAPKI-FAKZYNJA combination in a rare and underserved cancer indication. The durable responses and manageable safety profile position the therapy as a potential standard of care for recurrent LGSOC, pending confirmatory trial results. The company's focus on RAS/MAPK pathway-driven cancers aligns with broader industry trends toward precision oncology and targeted therapies.
What we're watching
- Clinical Validation
- Whether the durable efficacy data will support full FDA approval and expand the treatment options for LGSOC patients.
- Market Penetration
- The pace at which Verastem can commercialize AVMAPKI-FAKZYNJA CO-PACK in the rare LGSOC market.
- Pipeline Progress
- The outcomes of the ongoing Phase 3 RAMP 301 trial and the potential for the combination therapy in other cancer indications.
Related topics